Group 1 - Shanghai Moyang Biotechnology Co., Ltd. has successfully completed a new round of financing amounting to several hundred million yuan, attracting notable investment institutions such as a well-known domestic top fund, Huagai Capital, and BlueRun Ventures [1][2] - The financing will primarily be used to expand the marketing team, enhance global market coverage, and accelerate the R&D process for the next generation of products in the regenerative medical aesthetics field [2] - The company’s product, Youfa Lan Magic CC Needle, is the first in China to receive a Class III medical device registration certificate from the National Medical Products Administration (NMPA) for aesthetic indications, showcasing its commercial potential [1][2] Group 2 - The innovative "raspberry-like mesoporous microsphere structure" design allows for precise control of the particle size (30-35μm), porosity (74%), and the number of microspheres per unit volume (35 million/ml) of hydroxyapatite microspheres [1][2] - The company aims to leverage the support from new shareholders to accelerate the global commercial layout of core products and enhance market penetration in the regenerative medical aesthetics sector [2] - The chairman of the company expressed confidence in the future development potential of the medical aesthetics industry, emphasizing a mission to return medical aesthetics to its medical essence through innovative technology [2]